Podcasts about mozilla firefox

In this CME podcast episode, Dr. Andrew Cutler interviews Dr. Phillip Coffin, Director of the Center on Substance Use and Health in San Francisco, CA, about the management of stimulant use disorders. They explore the challenges of treatment and highlight the importance of harm reduction strategies to enhance patients' quality of life.  CME credit is available to NEI Members only.   Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Summarize pharmacologic and behavioral treatment strategies for stimulant use disorders, particularly methamphetamine and cocaine Evaluate the evidence base for current and investigational medications used in clinical trials and real-world settings Apply harm reduction principles and integrated care models to improve outcomes for patients with stimulant use disorders in diverse clinical settings Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: June 18, 2025*   Expiration: June 17, 2028 *NEI and HMP Education maintain a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-02.  Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until June 17, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD, LFAPA specializing in psychiatry, forensic, addiction to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Phillip Coffin, MD, MIA Director of Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA No financial relationships to disclose. The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, Stephen Daniels and Bahgwan Bahroo, MD, LFAPA. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Below is the information on the fourth edition of this great resource copied from this Carroll Center website: https://carroll.org/product/the-windows-screen-reader-primer-all-the-basics-and-more-digital-copy/ The fourth edition of The Windows Screen Reader Primer: All the Basics and More is now out. We are making it available to you for free in Word and ePub formats. It is authored by David Kingsbury, an Assistive Technology Instructor at the Carroll Center for the Blind. The book is meant to help beginning and intermediate JAWS, NVDA, and Windows Narrator users work more effectively with the most important PC applications. These applications include the Windows operating system, the four primary Office Suite applications (Word, Outlook, Excel and PowerPoint), popular Google applications, and the three most commonly used web browsers (Google Chrome, Microsoft Edge, and Mozilla Firefox). Cloud-based file-sharing programs such as Dropbox, OneDrive, and Google Drive are also covered. So too is Adobe Acrobat Reader for accessing PDF files. And participating in, scheduling, and hosting Zoom meetings. New topics in this edition include coverage of FS Companion, the New Outlook, using advanced Excel functions, and A substantially revised chapter on artificial intelligence (AI) reflecting some of the major changes that have occurred over the past year. Presenter Contact Info Email: david.kingsbury@carroll.org

This program is supported by educational grants from Amicus Therapeutics, Inc. and Chiesi USA Inc.Fabry disease is an inherited lysosomal storage disease caused by mutations in the GLA gene, disrupting the function of the enzyme, α-galactosidase. This results in the accumulation of globotriaosylceramide (GL-3) and its deacylated form, globotriaosylsphingosine (lyso-GL-3), leading to progressive disruption of multiple organ systems. There are currently three treatment options available for Fabry disease, including two enzyme replacement therapies, agalsidase beta and pegunigalsidase alfa, and a chaperone therapy, migalastat. There are also other treatments in development (e.g., gene therapy, other enzyme replacement therapies) and some that are available in other countries (e.g., agalsidase alfa). Due to the small patient population and variability in Fabry disease severity, it is challenging to develop properly powered, placebo-controlled clinical trials. As such, data shared at conferences like WORLDSymposium 2025 are crucial for guiding best practices in this disease area. This program, led by Dr. Eric Wallace, provides a summary of clinically relevant data presented at WORLDSymposium 2025 that can enhance the care of patients with Fabry disease.  Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology, nephrology, cardiology, gastroenterology, ophthalmology, and dermatology. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to: Describe the latest research being presented to better manage individuals with Fabry disease and its clinical relevance.Eric Wallace, MDProfessor of MedicineDepartment of NephrologyUniversity of Alabama Medical SchoolDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Wallace discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: Sanofi-Genzyme, Chiesi, Kyowa Kirin, Sangamo, NateraGrant/Research Support: Sanofi-Genzyme, Chiesi, Uniqure, Idorsia, Amicus Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.Hardware/Software RequirementsWindows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

video: https://youtu.be/PtP_jOlAIHE Comment on the TWIL Forum (https://thisweekinlinux.com/forum) This week in Linux, we have a lot of cool stuff to talk about. First, we're going to talk about the future of KDE Plasma. Then we're going to go into the future of OpenSUSE because Leap 16 beta has been released and the final version will be coming out this year. Then we'll also have a new version of Mozilla Firefox. And also we have some interesting news from the Oregon State University because there's some potential risk of closure of their Open Source Lab, which would be a shame. And then we're also going to talk about Redis because they're back in the news this week because they want to redo with Open Source. All of this and more on This Week in Linux, the weekly news show that keeps you up to date with what's going on in the Linux and Open Source world. Now let's jump right into Your Source for Linux GNews. Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/7cb90299-be53-43c6-90d5-019ad4489590.mp3) Support the Show Become a Patron = tuxdigital.com/membership (https://tuxdigital.com/membership) Store = tuxdigital.com/store (https://tuxdigital.com/store) Chapters: 00:00 Intro 00:52 Future of KDE Plasma: LTS, Telementry, & more 07:45 openSUSE Leap 16 Beta Released 13:49 Trinity Desktop R14.1.4 Released 17:17 Sandfly Security, agentless Linux security 19:15 Mozilla Firefox 138 Released 27:09 OSU Open Source Lab At Risk Of Closure 31:46 Redis wants a Redo with Open Source 37:28 Red Hat Summit 2025 39:47 Support the show Links: Future of KDE Plasma: LTS, Telementry, & more https://pointieststick.com/2025/05/01/notes-from-the-graz-plasma-sprint/ (https://pointieststick.com/2025/05/01/notes-from-the-graz-plasma-sprint/) openSUSE Leap 16 Beta Released https://news.opensuse.org/2025/04/30/leap-16-enters-beta/ (https://news.opensuse.org/2025/04/30/leap-16-enters-beta/) https://news.opensuse.org/2025/05/02/tw-monthly-update-april/ (https://news.opensuse.org/2025/05/02/tw-monthly-update-april/) Trinity Desktop R14.1.4 Released https://www.trinitydesktop.org/ (https://www.trinitydesktop.org/) https://www.trinitydesktop.org/newsentry.php?entry=2025.04.27 (https://www.trinitydesktop.org/newsentry.php?entry=2025.04.27) Sandfly Security, agentless Linux security https://thisweekinlinux.com/sandfly (https://thisweekinlinux.com/sandfly) https://destinationlinux.net/409 (https://destinationlinux.net/409) Mozilla Firefox 138 Released https://www.mozilla.org/en-US/firefox/138.0/releasenotes/ (https://www.mozilla.org/en-US/firefox/138.0/releasenotes/) https://blog.mozilla.org/en/firefox/tab-groups-community/ (https://blog.mozilla.org/en/firefox/tab-groups-community/) https://www.howtogeek.com/235670/organize-manage-your-firefox-tabs-like-a-pro-with-the-tab-groups-add-on/ (https://www.howtogeek.com/235670/organize-manage-your-firefox-tabs-like-a-pro-with-the-tab-groups-add-on/) OSU Open Source Lab At Risk Of Closure https://osuosl.org/blog/osl-future/ (https://osuosl.org/blog/osl-future/) Redis wants a Redo with Open Source https://redis.io/blog/agplv3/ (https://redis.io/blog/agplv3/) https://antirez.com/news/151 (https://antirez.com/news/151) https://youtu.be/r67MRruNhow (https://youtu.be/r67MRruNhow) Red Hat Summit 2025 https://www.redhat.com/en/summit (https://www.redhat.com/en/summit) https://www.redhat.com/en/blog/red-hat-summit-ansiblefest-2025-ansible-sessions-you-dont-want-miss (https://www.redhat.com/en/blog/red-hat-summit-ansiblefest-2025-ansible-sessions-you-dont-want-miss) Support the show https://tuxdigital.com/membership (https://tuxdigital.com/membership) https://store.tuxdigital.com/ (https://store.tuxdigital.com/)

video: https://youtu.be/MGKUyzSei_4 Comment on the TWIL Forum (https://thisweekinlinux.com/forum) This week in Linux, we have a lot of great news to talk about. First, Thunderbird is launching their own email service. KDE is working on making their own Plasma Login Manager. CachyOS has a new release out. We also have another release out for the Mozilla Firefox browser, which has a lot of cool stuff in there I can't wait to tell you about. And also the Dash to Panel extension. There was a little bit of drama that happened with it. It is now back and ready to go. all of this and so much more on this episode of This Week in Linux, the weekly news show that keeps you up to date with what's going on in the Linux and open source world. Now let's jump right into Your Source for Linux GNews. Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/156b6f62-4ef1-48e5-9278-6860b9516e21.mp3) Support the Show Become a Patron = tuxdigital.com/membership (https://tuxdigital.com/membership) Store = tuxdigital.com/store (https://tuxdigital.com/store) Chapters: 00:00 Intro 00:46 Thunderbird is Launching Email Service 05:46 KDE Working on a new Plasma Login Manager 09:55 CachyOS March 2025 Release 12:29 Sandfly Security, agentless Linux security [ad] 14:12 Mozilla Firefox 137 Released 26:28 Zorin OS Sponsors Dash to Panel 31:28 GoboLinux 017.01 Released 34:50 XZ Utils 5.8 Released 37:25 Support the show Links: Thunderbird is Launching Email Service https://blog.thunderbird.net/2025/04/thundermail-and-thunderbird-pro-services/ (https://blog.thunderbird.net/2025/04/thundermail-and-thunderbird-pro-services/) KDE Working on a new Plasma Login Manager https://blog.davidedmundson.co.uk/blog/a-roadmap-for-a-modern-plasma-login-manager/ (https://blog.davidedmundson.co.uk/blog/a-roadmap-for-a-modern-plasma-login-manager/) https://mail.kde.org/pipermail/plasma-devel/2025-March/123667.html (https://mail.kde.org/pipermail/plasma-devel/2025-March/123667.html) CachyOS March 2025 Release https://cachyos.org/blog/2503-march-release/ (https://cachyos.org/blog/2503-march-release/) Sandfly Security, agentless Linux security [ad] https://thisweekinlinux.com/sandfly (https://thisweekinlinux.com/sandfly) https://destinationlinux.net/409 (https://destinationlinux.net/409) Mozilla Firefox 137 Released https://www.mozilla.org/en-US/firefox/137.0/releasenotes/ (https://www.mozilla.org/en-US/firefox/137.0/releasenotes/) https://tuxdigital.com/videos/secret-feature-that-makes-firefox-bookmarks-awesome/ (https://tuxdigital.com/videos/secret-feature-that-makes-firefox-bookmarks-awesome/) https://tuxdigital.com/videos/firefox-container-tabs-the-best-browser-feature-heres-how-to-use-them/ (https://tuxdigital.com/videos/firefox-container-tabs-the-best-browser-feature-heres-how-to-use-them/) Zorin OS Sponsors Dash to Panel https://github.com/home-sweet-gnome/dash-to-panel (https://github.com/home-sweet-gnome/dash-to-panel) https://www.theregister.com/2025/03/30/zorinanddashtopanel/ (https://www.theregister.com/2025/03/30/zorin_and_dash_to_panel/) GoboLinux 017.01 Released https://gobolinux.org/index.html (https://gobolinux.org/index.html) https://gobolinux.org/releasenotes017.01.html (https://gobolinux.org/release_notes_017.01.html) XZ Utils 5.8 Released https://git.tukaani.org/?p=xz.git;a=blob;f=NEWS (https://git.tukaani.org/?p=xz.git;a=blob;f=NEWS) https://tukaani.org/xz/ (https://tukaani.org/xz/) Support the show https://tuxdigital.com/membership (https://tuxdigital.com/membership) https://store.tuxdigital.com/ (https://store.tuxdigital.com/)

In this CME podcast, Dr. Andrew Cutler and Dr. Roger McIntyre discuss the use of potentially unsafe drug combinations in patients with treatment-resistant psychiatric conditions. They review situations where complex medication regimens may be necessary and how clinicians may proceed in these instances. By addressing these topics, the podcast offers guidance on balancing the potential benefits of combination therapies with the risks associated with polypharmacy in psychiatric care.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Identify common potentially unsafe drug combinations that may be considered in treatment-resistant cases Evaluate the risks and benefits of prescribing potentially unsafe drug combinations for treatment-resistant patients, considering factors such as efficacy, adverse effects, and patient-specific characteristics Develop strategies to monitor and manage patients prescribed potentially unsafe drug combinations Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour. Released: March 26, 2025*   Expiration: March 25, 2028 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-01 Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until March 25, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, and cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education take responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, ON, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, NEI and HMP planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, and Steven S. Simring, MD, MPH. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Silicon Valley's culture and the rapid rise of AI are reshaping leadership and business landscapes. In this episode of Seek Go Create, we welcome back Silicon Valley veteran, Netflix cofounder, and executive coach Jim Cook. With over thirty years of experience, Jim dives into the seismic shifts over the past five years, discussing the implications of AI, the evolution of leadership, and his insights on the intersection of technology and human curiosity. Whether you're a tech enthusiast, a leader seeking inspiration, or someone curious about the future of work, this conversation is a must-listen."Maturity isn't an age—it's the ability to take risks, stay curious, and not worry about what others think." - Jim Cook Access all show and episode resources HEREAbout Our Guest:Jim Cook is a seasoned Silicon Valley veteran and co-founder of Netflix, known for his strategic acumen in bridging the gap between vision and execution in tech startups. With over thirty years of experience, Jim has demonstrated exceptional leadership as a founder, CEO of BenchBoard Executive Coaching, and director of the Alliance of CEOs. His extensive background includes pivotal roles at Intuit, Mozilla Firefox, and other renowned organizations, making him a well-respected figure in tech leadership and innovation. Jim continues to share his wealth of knowledge through coaching, helping to mold the next generation of leaders. Reasons to Listen: Insights from a Silicon Valley Veteran: Discover the unique perspectives of Jim Cook, Netflix cofounder, as he shares lessons from over 30 years in tech and leadership innovation, with a special focus on the evolution of AI and its impact on the industry.Navigating Crisis and Opportunity: Learn how the dynamic landscape of Silicon Valley adapted during major events like COVID-19 and how it continues to innovate in response to global challenges, providing valuable lessons in resilience and adaptability.The Future of Leadership and Technology: Engage with the forward-thinking discussion on the integration of AI in business and government, and explore how curiosity, risk-taking, and maturity are crucial for future leaders in an ever-evolving digital world.Episode Resources & Action Steps:Resources Mentioned:Cook's PlayBooks on Substack: Jim Cook writes a series on leadership and scaling operations. A specific series mentioned is "Leading with Powerful Questions." This is a great resource for those interested in leadership development and effective questioning techniques.Jim Cook on Seek Go Create - Episode from January 27, 2020.Deep Research and Operator by OpenAI: These are AI tools mentioned by Jim Cook that can aid in research and automation tasks. They offer functionalities like conducting deep research on topics and automating repetitive browser tasks, which can significantly increase productivity.Action Steps:Stay Curious and Ask Questions: Jim Cook emphasizes the importance of curiosity and asking questions in both personal and professional growth. Listeners are encouraged to cultivate a mindset of curiosity and engage in continuous learning.Explore AI Tools: Experiment with AI tools like Deep Research and Operator to see how they can enhance productivity and efficiency in daily tasks or professional workflows....

Coming up in this episode * Syncing the Notes * The History of Snaps * And How Much We Absolutely Adore Them 0:00 Cold Open 1:34 Seeking Syncthing 16:42 The History of Snaps 33:52 How'd 9 Years of Snaps Go? 1:01:54 Next Time 1:04:49 Stinger The Video Version https://youtu.be/izDzKkuEyRw It is all about the notes Leo goes back to basics and uses SyncThing (https://syncthing.net/) to move his markdown files around that he edits using a standard text editor (https://code.visualstudio.com/).

video: https://youtu.be/Anw68ThdGcs Comment on the TWIL Forum (https://thisweekinlinux.com/forum) This week in Linux, we have a ton to talk about. First, we're gonna be talking about building Linux from Scratch. I mean, not walking through that or anything. It's the project called that. Also, the Xen project has a new version of their hypervisor out, and Mozilla is back in the news this week with the latest release of Firefox with 136. Plus, Linux Mint is talking about redesigning their Cinnamon app menu, and so much more, including, Microsoft is hanging up on Skype forever. All of this and more on This Week in Linux, the weekly news show that keeps you up to date with what's going on in the Linux and Open Source world. So let's jump right into Your Source for Linux GNews Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/0e2fe0b7-a965-405b-ba93-57510d445740.mp3) Support the Show Become a Patron = tuxdigital.com/membership (https://tuxdigital.com/membership) Store = tuxdigital.com/store (https://tuxdigital.com/store) Chapters: 00:00 Intro 00:45 What's new at TuxDigital 00:59 Interview with Craig Rowland on DL 01:25 3 new videos on the channel 02:30 TWIL 300 Giveaway 03:14 Linux From Scratch 12.3 Released 06:58 Xen Project 4.20 Released 09:35 Mozilla Firefox 136 Released 12:49 Sandfly Security, agentless Linux security 14:55 Linux Mint to Redesign Cinnamon App Menu 19:07 Thunderbird 136 Released 21:25 PipeWire 1.4 Released 25:11 Skype is being shutdown 29:37 Support the show Links: Interview with Craig Rowland on DL https://destinationlinux.net/409 (https://destinationlinux.net/409) 3 new videos on the channel Flatpaks, Snaps, & AppImages: "Do we really need these Universal App Formats?": https://youtu.be/so_f6OtRWRo (https://youtu.be/so_f6OtRWRo) How to Rename Files like a Pro in Linux (+ my formula for organizing & declutter): https://youtu.be/zTaRHI4j7Sg (https://youtu.be/zTaRHI4j7Sg) Reacting to PewDiePie, one of the biggest YouTubers switches to Linux: https://youtu.be/avMQYgadLFc (https://youtu.be/avMQYgadLFc) TWIL 300 Giveaway https://thisweekinlinux.com/300giveaway (https://thisweekinlinux.com/300giveaway) Linux From Scratch 12.3 Released https://linuxfromscratch.org/ (https://linuxfromscratch.org/) Xen Project 4.20 Released https://www.linuxfoundation.org/press/xen-project-announces-xen-420-release (https://www.linuxfoundation.org/press/xen-project-announces-xen-420-release) https://wiki.xenproject.org/wiki/XenProject4.20ReleaseNotes (https://wiki.xenproject.org/wiki/Xen_Project_4.20_Release_Notes) Mozilla Firefox 136 Released https://www.mozilla.org/en-US/firefox/136.0/releasenotes/ (https://www.mozilla.org/en-US/firefox/136.0/releasenotes/) Linux Mint to Redesign Cinnamon App Menu https://blog.linuxmint.com/?p=4811 (https://blog.linuxmint.com/?p=4811) https://www.omgubuntu.co.uk/2025/03/cinnamon-desktop-app-menu-redesign (https://www.omgubuntu.co.uk/2025/03/cinnamon-desktop-app-menu-redesign) Thunderbird 136 Released https://www.thunderbird.net/en-US/thunderbird/136.0/releasenotes/ (https://www.thunderbird.net/en-US/thunderbird/136.0/releasenotes/) PipeWire 1.4 Released https://pipewire.org/ (https://pipewire.org/) https://gitlab.freedesktop.org/pipewire/pipewire/-/commit/df1c36aec2aaf9e2eb1596b6b55e72c15fb2088a (https://gitlab.freedesktop.org/pipewire/pipewire/-/commit/df1c36aec2aaf9e2eb1596b6b55e72c15fb2088a) Skype is being shutdown https://www.omgubuntu.co.uk/2025/02/skype-hangs-up-for-good-on-may-5 (https://www.omgubuntu.co.uk/2025/02/skype-hangs-up-for-good-on-may-5) https://www.theverge.com/news/621353/microsoft-skype-shutting-down-retirement-may-2025 (https://www.theverge.com/news/621353/microsoft-skype-shutting-down-retirement-may-2025) Support the show https://tuxdigital.com/membership (https://tuxdigital.com/membership) https://store.tuxdigital.com/ (https://store.tuxdigital.com/)

Det senaste decenniet har användandet av Mozillas webbläsare Firefox sjunkit stadigt. Allt färre internetanvändare väljer Firefox för att surfa på webben. Det är inte bara användarandelen som krymper i takt med att fler börjar använda internet. Till och med antalet månatligt aktiva Firefox-användare minskar år för år. En användargrupp som ändå har hållit fast vid Mozilla Firefox är användarna som värnar extra mycket om sin personliga integritet. Många av dessa användare förargades förra veckan när Mozilla valde att införa kontroversiella användarvillkor för Firefox. Trycket blev så stort att Mozilla tvingades dra tillbaka och revidera några av de nya villkoren. I veckans avsnitt av Bli säker-podden pratar Peter och Nikka om Mozillas hantering av situationen. Nikka blickar tillbaka och läser upp Mozillas löften från tidigare år – löften som nu klingar falskt. Podduon diskuterar hur kontroversen påverkar Firefox överlevnadschanser och ställer sig frågan: begick Mozilla precis sitt allra sista misstag? Se fullständiga shownotes på https://go.nikkasystems.com/podd290.

video: https://youtu.be/v7ZLEAxoW14 Comment on the TWIL Forum (https://thisweekinlinux.com/forum) This week in Linux, we have a lot to talk about with the Linux kernel getting, or maybe not getting, Rusty. There's a little bit of drama there. Also, the Void Linux project has a new release of their distribution. EA has provided an update regarding Apex Legends and Linux. It's not great news, but we're gonna talk about it. There's also a tiny Linux kernel tweak that could save 30% on power use for data centers. And all of this and so much more on this week in Linux, the weekly news show that keeps you up to date with what's going on in the Linux and Open Source world. Now let's jump right into Your Source for Linux GNews. Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/2def3851-3faa-48a3-9ee3-3cc889d253b6.mp3) Support the Show Become a Patron = tuxdigital.com/membership (https://tuxdigital.com/membership) Store = tuxdigital.com/store (https://tuxdigital.com/store) Chapters: 00:00 Intro 00:41 Linux Kernel gets some Rusty Drama 03:48 Void Linux 20250202 Released 06:13 Many Open Source Projects Scramble to Find Funding 12:14 Sandfly Security, agentless Linux security [ad] 13:45 Mozilla Firefox 135 Released 19:48 This tiny Linux kernel tweak could SAVE 30% on Power Use for Datacenters! 21:10 Ghostty 1.1.0 Released 24:06 Let's Encrypt Ending Expiration Notification Emails 28:12 Apex Legends Is Losing Players—So They're Blaming Linux? 29:39 Support the show Links: Linux Kernel gets some Rusty Drama https://www.phoronix.com/news/Asahi-Linux-Lead-No-Upstream (https://www.phoronix.com/news/Asahi-Linux-Lead-No-Upstream) https://www.reddit.com/r/linux/comments/1ijxber/linustorvaldstakeonthelatestrustkernel_drama/ (https://www.reddit.com/r/linux/comments/1ijxber/linus_torvalds_take_on_the_latest_rustkernel_drama/) Void Linux 20250202 Released https://voidlinux.org/news/2025/02/new-images.html (https://voidlinux.org/news/2025/02/new-images.html) Many Open Source Projects Scramble to Find Funding https://gitlab.freedesktop.org/freedesktop/freedesktop/-/issues/2011 (https://gitlab.freedesktop.org/freedesktop/freedesktop/-/issues/2011) https://www.phoronix.com/news/2025-XOrg-FreeDesktop-Cloud (https://www.phoronix.com/news/2025-XOrg-FreeDesktop-Cloud) https://www.datacenterdynamics.com/en/news/equinix-to-kill-off-metal-by-june-2026/ (https://www.datacenterdynamics.com/en/news/equinix-to-kill-off-metal-by-june-2026/) https://arstechnica.com/gadgets/2025/02/popular-linux-orgs-freedesktop-and-alpine-linux-are-scrambling-for-new-web-hosting/ (https://arstechnica.com/gadgets/2025/02/popular-linux-orgs-freedesktop-and-alpine-linux-are-scrambling-for-new-web-hosting/) https://alpinelinux.org/posts/Seeking-Support-After-Equinix-Metal-Sunsets.html (https://alpinelinux.org/posts/Seeking-Support-After-Equinix-Metal-Sunsets.html) https://www.reddit.com/r/linux/comments/1iil0nk/alpineneedshelp/ (https://www.reddit.com/r/linux/comments/1iil0nk/alpine_needs_help/) Sandfly Security, agentless Linux security [ad] https://thisweekinlinux.com/sandfly (https://thisweekinlinux.com/sandfly) Mozilla Firefox 135 Released https://www.mozilla.org/en-US/firefox/135.0/releasenotes/ (https://www.mozilla.org/en-US/firefox/135.0/releasenotes/) https://www.omgubuntu.co.uk/2025/02/mozilla-firefox-135-released (https://www.omgubuntu.co.uk/2025/02/mozilla-firefox-135-released) https://www.theregister.com/2024/12/12/firefoxdonot_track/ (https://www.theregister.com/2024/12/12/firefox_do_not_track/) https://www.phoronix.com/news/Firefox-136-Beta (https://www.phoronix.com/news/Firefox-136-Beta) This tiny Linux kernel tweak could SAVE 30% on Power Use for Datacenters! https://youtu.be/OQa2cazPlNs (https://youtu.be/OQa2cazPlNs) Ghostty 1.1.0 Released https://ghostty.org/docs/install/release-notes/1-1-0 (https://ghostty.org/docs/install/release-notes/1-1-0) https://www.omgubuntu.co.uk/2025/02/ghostty-update-adds-server-side-decoration-support-on-linux (https://www.omgubuntu.co.uk/2025/02/ghostty-update-adds-server-side-decoration-support-on-linux) Let's Encrypt Ending Expiration Notification Emails https://letsencrypt.org/2025/01/22/ending-expiration-emails/ (https://letsencrypt.org/2025/01/22/ending-expiration-emails/) Apex Legends Is Losing Players—So They're Blaming Linux? https://youtu.be/Oz7AK_DZ9wU (https://youtu.be/Oz7AK_DZ9wU) Support the show https://tuxdigital.com/membership (https://tuxdigital.com/membership) https://store.tuxdigital.com/ (https://store.tuxdigital.com/)

Send us a textIt's our best of the best for the year 2004 where the internet's favorite new words take center stage

The company that pre-loads Chrome on Android, and makes ChromeOS, says Microsoft is "Dark" for pre-loading Edge on Windows.Interestingly: Apple Safari, Mozilla Firefox, & Brave are not involved. More from The Lunduke Journal: https://lunduke.com/ This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit lunduke.substack.com/subscribe

In this CME podcast, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the history of muscarinic receptor science in schizophrenia and how that informs the mechanisms of action of novel muscarinic-targeting drugs for this disorder. They also discuss the efficacy and safety of these drugs and provide practical strategies for prescribing xanomeline-trospium.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Discuss the history of muscarinic receptor science and the role of muscarinic receptors in schizophrenia treatment Differentiate novel and in-development muscarinic-targeting treatments for schizophrenia based on their unique mechanisms of action, efficacy, and tolerability data   Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 27, 2024*   Expiration: November 26, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-SCHIZ01  Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until November 26, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry and psychopharmacology — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Jonathan M. Meyer, MD Voluntary Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: AbbVie, Alkermes, Bristol Myers Squibb, Intra-Cellular, Neurocrine, Sumitomo, Teva Speakers Bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb, Intra-Cellular, Neurocrine, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Meghan M. Grady, BA, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an educational grant from Bristol Myers Squibb.

Jointly Provided by the American Academy of CME and CheckRare CE Inc.Support for this accredited continuing education activity has been made possible through educational grant from argenx US Inc. and UCB.Estimated time to complete: 0.25 hoursStart date: November 7, 2024End date: November 6, 2025This quarter-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, discusses the safety and efficacy of neonatal fragment crystallizable receptor (FcRn)-directed therapies for patient with myasthenia gravis.To obtain CME credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis-treatment-options/ Activity FacultyRichard J. Nowak, MD, MSDirector, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular MedicineDepartment of Neurology Yale School of Medicine New Haven, CTTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe the efficacy of the treatment options for MG that target FcRn.Compare the safety of the treatment options for MG that target FcRn.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Nowak discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBGrant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

Jointly Provided by American Academy of CME Inc and CheckRare CE Inc.Support for this accredited continuing education activity has been made possible through an educational grant from argenx US Inc. and UCB.Estimated time to complete: 0.50 hoursStart date: November 7, 2024End date: November 6, 2025This half-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, explains the role of  neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG) and how treatments that target FcRn are being used to manage patients with MG.To obtain credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis/ Activity FacultyRichard J. Nowak, MD, MSDirector, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular MedicineDepartment of Neurology Yale School of Medicine New Haven, CTTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe the role of FcRn in MG.Describe the efficacy of the treatment options for MG that target FcRn.Compare the safety of the treatment options for MG that target FcRn.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Nowak discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBGrant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

Jointly Provided by American Academy of CME Inc and CheckRare CE Inc.Support for this accredited continuing education activity has been made possible through an educational grant from argenx US Inc.and UCB.Estimated time to complete: 0.25 hoursStart date: November 7, 2024End date: November 6, 2025This quarter-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, explains the role of  neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG).To obtain CME credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis-pathophysiology/ Activity FacultyRichard J. Nowak, MD, MSDirector, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular MedicineDepartment of Neurology Yale School of Medicine New Haven, CTTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe the role of FcRn in MG.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Nowak discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBGrant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection.Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

In this CME episode, Drs. Andrew Cutler and Roger McIntyre discuss the challenges and importance of diagnosing bipolar disorder as early as possible in the course of the illness. They also review strategies to achieve a correct diagnosis to provide the most efficacious and tolerable treatments available for bipolar disorder. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Employ effective screening tools and assessment strategies to enhance diagnostic accuracy and achieve early diagnosis of bipolar disorder Develop patient-centered treatment plans that incorporate current evidence and individual patient factors Utilize shared decision-making approaches to optimize treatment outcomes for patients with bipolar disorder Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 01, 2024*   Expiration: October 31, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-BD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 31, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, Ontario, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.

In this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: October 23, 2024*   Expiration: October 22, 2027 *NEI maintains a record of participation for six (6) years.   CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-TD   Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options) The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.

Mozilla Firefox is an open-source web browser developed by the Mozilla Foundation. Since its first major release in 2004, it has stood out on the browser landscape for its emphasis on privacy, security, and customization. Brian Grinstead is a Senior Principal Engineer at Mozilla. He joins the podcast with Kevin Ball to talk about the The post Firefox Software Architecture with Brian Grinstead appeared first on Software Engineering Daily.

Mozilla Firefox is an open-source web browser developed by the Mozilla Foundation. Since its first major release in 2004, it has stood out on the browser landscape for its emphasis on privacy, security, and customization. Brian Grinstead is a Senior Principal Engineer at Mozilla. He joins the podcast with Kevin Ball to talk about the The post Firefox Software Architecture with Brian Grinstead appeared first on Software Engineering Daily.

In this CME episode, Dr. Andrew Cutler interviews Dr. Charles Vega about the challenges of identifying bipolar disorder in primary care and how to over come them. They also discuss strategies for initiating and managing pharmacological treatment long term in collaboration with patients and psychiatric specialists. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objective: After completing this educational activity, you should be better able to: Identify the key symptoms and diagnostic criteria for bipolar disorder to accurately screen and diagnose patients presenting in primary care settings Describe strategies for initiating and managing pharmacological treatment of bipolar disorder, including appropriate use of mood stabilizers, antipsychotics, and monitoring for side effects and adherence Explain the role of the primary care provider in coordinating care for bipolar disorder patients, including providing psychoeducation, determining appropriate level of care, and collaborating with mental health specialists when needed Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 45 minutes Released: September 04, 2024*   Expiration: September 03, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-PrimCare Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 0.75 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credits™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.75 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 0.75 contact hour (.075 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 0.75 AAPA Category 1 credit. Approval is valid until September 03, 2027. PAs should only claim credit commensurate with the extent of their participation. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Charles P. Vega, MD Clinical Professor, School of Medicine, University of California - Irvine, Orange, CA Consultant/Advisor: Boehringer Ingelheim, Exact Sciences The remaining Planning Committee member(s), Content Editor(s), Peer Reviewer(s), and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, Samantha Joy, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

20240808 NVDA Basics–Mozilla Firefox Originally Broadcasted August 8, 2024, on ACB Media 5   This week, we discussed Mozilla Firefox. For details for this week's class: Click here

video: https://youtu.be/bfXXS5Z1JMc Forum Discussion Thread (https://forum.tuxdigital.com/t/271-fedora-metrics-wayland-zed-ide-gnome-finally-revamping-extensions-site-more-linux-news/6334) This week in Linux, Fedora announced some plans for future releases that may be controversial. There's a new IDE available for Linux that might turn some heads. GNOME's Extensions Website is getting a redesign but is it any good? All of this and more on This Week in Linux, the weekly news show that keeps you up to date with what's going on in the Linux and Open Source world. Now let's jump right into Your Source for Linux GNews! Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/c1fc47ca-d7d4-496e-ad49-befaaa8b7686.mp3) Support the Show Become a Patron = tuxdigital.com/membership (https://tuxdigital.com/membership) Store = tuxdigital.com/store (https://tuxdigital.com/store) Chapters: 00:00 Intro 00:33 Ubuntu App Center Can Now Install DEBs 02:10 Fedora Workstation: Opt-In Metrics & Wayland Only 07:41 Mozilla Firefox 128 ESR & Thunderbird 128 ESR 13:58 Zed IDE is now available for Linux 17:22 GNOME Extensions Website Redesign Coming 20:26 DXVK 2.4 Released 22:30 15 Years of GamingOnLinux.com 24:26 Outro Links: Ubuntu App Center Can Now Install DEBs https://www.omgubuntu.co.uk/2024/07/app-center-update-adds-deb-install-support (https://www.omgubuntu.co.uk/2024/07/app-center-update-adds-deb-install-support) Fedora Workstation: Opt-In Metrics & Wayland Only Opt-In Metrics https://discussion.fedoraproject.org/t/f42-change-proposal-opt-in-metrics-for-fedora-workstation-system-wide/124325 (https://discussion.fedoraproject.org/t/f42-change-proposal-opt-in-metrics-for-fedora-workstation-system-wide/124325) https://lists.fedoraproject.org/archives/list/devel@lists.fedoraproject.org/thread/RENZQGQTUPVNNVNN6GI6EC4K632S6SOU/ (https://lists.fedoraproject.org/archives/list/devel@lists.fedoraproject.org/thread/RENZQGQTUPVNNVNN6GI6EC4K632S6SOU/) https://fedoraproject.org/wiki/Changes/Metrics (https://fedoraproject.org/wiki/Changes/Metrics) Wayland only https://fedoraproject.org/wiki/Changes/WaylandOnlyGNOMEWorkstationMedia (https://fedoraproject.org/wiki/Changes/WaylandOnlyGNOMEWorkstationMedia) Mozilla Firefox 128 ESR & Thunderbird 128 ESR Firefox https://www.mozilla.org/en-US/firefox/128.0/releasenotes/ (https://www.mozilla.org/en-US/firefox/128.0/releasenotes/) https://9to5linux.com/mozilla-firefox-128-is-now-available-for-download-heres-whats-new (https://9to5linux.com/mozilla-firefox-128-is-now-available-for-download-heres-whats-new) https://www.omgubuntu.co.uk/2024/07/mozilla-firefox-128-released-this-is-mostly-whats-new (https://www.omgubuntu.co.uk/2024/07/mozilla-firefox-128-released-this-is-mostly-whats-new) Thunderbird https://www.thunderbird.net/en-US/thunderbird/128.0esr/releasenotes/ (https://www.thunderbird.net/en-US/thunderbird/128.0esr/releasenotes/) https://9to5linux.com/mozilla-thunderbird-128-esr-is-now-available-for-download-heres-whats-new (https://9to5linux.com/mozilla-thunderbird-128-esr-is-now-available-for-download-heres-whats-new) https://www.omgubuntu.co.uk/2024/07/thunderbird-128-released-with-major-changes (https://www.omgubuntu.co.uk/2024/07/thunderbird-128-released-with-major-changes) Zed IDE is now available for Linux https://zed.dev/ (https://zed.dev/) https://zed.dev/blog/zed-on-linux (https://zed.dev/blog/zed-on-linux) https://www.omgubuntu.co.uk/2024/07/zed-editor-linux-released (https://www.omgubuntu.co.uk/2024/07/zed-editor-linux-released) https://www.gamingonlinux.com/2024/07/popular-multiplayer-code-editor-zed-gets-a-linux-release/ (https://www.gamingonlinux.com/2024/07/popular-multiplayer-code-editor-zed-gets-a-linux-release/) https://www.phoronix.com/news/Zed-Native-Linux-Builds (https://www.phoronix.com/news/Zed-Native-Linux-Builds) GNOME Extensions Website Redesign Coming https://www.omgubuntu.co.uk/2024/07/gnome-extensions-website-redesign-2024 (https://www.omgubuntu.co.uk/2024/07/gnome-extensions-website-redesign-2024) DXVK 2.4 Released https://github.com/doitsujin/dxvk/releases/tag/v2.4 (https://github.com/doitsujin/dxvk/releases/tag/v2.4) https://9to5linux.com/dxvk-2-4-released-with-non-native-refresh-rate-emulation-direct3d-8-support (https://9to5linux.com/dxvk-2-4-released-with-non-native-refresh-rate-emulation-direct3d-8-support) https://www.gamingonlinux.com/2024/07/dxvk-24-brings-d8vk-for-direct3d-8-support-frame-rate-limiter-adjustments-lots-of-game-fixes/ (https://www.gamingonlinux.com/2024/07/dxvk-24-brings-d8vk-for-direct3d-8-support-frame-rate-limiter-adjustments-lots-of-game-fixes/) https://www.phoronix.com/news/DXVK-2.4-Released (https://www.phoronix.com/news/DXVK-2.4-Released) Happy 15th Anniversary to GamingOnLinux https://www.gamingonlinux.com/2024/07/happy-birthday-to-gamingonlinux-15-years-old-today/ (https://www.gamingonlinux.com/2024/07/happy-birthday-to-gamingonlinux-15-years-old-today/)

In this CME episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo about the current landscape of tardive dyskinesia, including screening, diagnosis, and treatment. Practical strategies based on the latest data are reviewed at length, particularly for long-term management of tardive dyskinesia.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Consider the individual patient profile and symptoms when determining a treatment plan for patients with tardive dyskinesia Integrate latest safety, efficacy, and tolerability data of VMAT2 inhibitors into decision-making processes when considering treatment options for tardive dyskinesia Evaluate practical strategies for patient follow-up and long-term VMAT2 inhibitor treatment Evaluate and integrate recent updates and advancements regarding evidence-based treatment strategies for tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour Released: June 26, 2024*   Expiration: June 25, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-02-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until June 25, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.0 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Laxman B. Bahroo, DO, MS, FAAN Professor and Residency Program Director, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC Consultant/Advisor: AbbVie, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Revance, Supernus Speakers Bureau: AbbVie, Acadia, Acorda, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Supernus, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, Brielle Calleo, and Andrea Zimmerman, EdD. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

https://youtu.be/4uNJpbe4eSk Forum Discussion Thread (https://forum.tuxdigital.com/t/267-raspberry-pi-ipo-tuxedo-snapdragon-laptop-valve-lawsuit-opensuse-leap-more-linux-news/6268) This week in Linux we saw some big releases from openSUSE, Mozilla, and more. We're also going to take a look at a new prototype laptop from TUXEDO Computers that I am very excited about. Then we'll jump into everyone's favorite segment, Legal News, because Valve is being sued for apparently overcharging gamers even though its much cheaper than buying games on console . . . hmm. All of this and more on this episode of This Week in Linux, Your Source for Linux GNews! Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/518b0de2-780e-4d90-a34f-b8be1eb92f07.mp3) Sponsored by: Kolide - thisweekinlinux.com/kolide (https://thisweekinlinux.com/kolide) Want to Support the Show? Become a Patron = https://tuxdigital.com/membership (https://tuxdigital.com/membership) Store = https://tuxdigital.com/store (https://tuxdigital.com/store) Chapters: 00:00 Intro 00:40 Raspberry Pi IPO on London Stock Exchange 01:37 Tuxedo Snapdragon X Elite Laptop Prototype 05:55 openSUSE Leap 15.6 Released 09:17 Sponsored by Kolide 10:57 Lawsuit filed against Valve 24:38 Linus Torvalds Merging Extensible Scheduler “sched_ext” 29:07 Mozilla Firefox 127 Released 34:14 NetXMS 5.0.4 Released 37:22 Outro Links: Raspberry Pi IPO on London Stock Exchange https://www.raspberrypi.com/news/raspberry-pi-ipo/ (https://www.raspberrypi.com/news/raspberry-pi-ipo/) https://www.londonstockexchange.com/stock/RPI/raspberry-pi-holdings-plc... (https://www.londonstockexchange.com/stock/RPI/raspberry-pi-holdings-plc/company-page) https://frontpagelinux.com/news/raspberry-pi-goes-public-with-ipo-on... (https://frontpagelinux.com/news/raspberry-pi-goes-public-with-ipo-on-london-stock-exchange/) Tuxedo Snapdragon X Elite Laptop Prototype https://www.tuxedocomputers.com/en/TUXEDO-on-ARM-is-coming.tuxedo (https://www.tuxedocomputers.com/en/TUXEDO-on-ARM-is-coming.tuxedo) https://www.qualcomm.com/developer/blog/2024/05/upstreaming-linux-kernel.. (https://www.qualcomm.com/developer/blog/2024/05/upstreaming-linux-kernel-support-for-the-snapdragon-x-elite) https://destinationlinux.net/374 (https://destinationlinux.net/374) openSUSE Leap 15.6 Released https://get.opensuse.org/leap/15.6/ (https://get.opensuse.org/leap/15.6/) https://news.opensuse.org/2024/06/12/leap-unveils-choices-for-users/ (https://news.opensuse.org/2024/06/12/leap-unveils-choices-for-users/) https://en.opensuse.org/Features_15.6 (https://en.opensuse.org/Features_15.6) https://frontpagelinux.com/news/opensuse-leap-15-6-released-heres-what-you-need... (https://frontpagelinux.com/news/opensuse-leap-15-6-released-heres-what-you-need-to-know/) Lawsuit filed against Valve https://www.gamingonlinux.com/2024/06/valve-faces-a-656-million-lawsuit-in-the-uk... (https://www.gamingonlinux.com/2024/06/valve-faces-a-656-million-lawsuit-in-the-uk-for-overcharging-14-million-pc-gamers) Linus Torvalds Merging Extensible Scheduler "sched_ext" https://lore.kernel.org/lkml/CAHk-=wg8APE61e5Ddq5mwH55Eh0ZLDV4Tr+c6_gFS7g2AxnuHQ... (https://lore.kernel.org/lkml/CAHk-=wg8APE61e5Ddq5mwH55Eh0ZLDV4Tr+c6_gFS7g2AxnuHQ@mail.gmail.com/) https://frontpagelinux.com/news/linus-torvalds-merging-extensible-scheduler-sched_ext... (https://frontpagelinux.com/news/linus-torvalds-merging-extensible-scheduler-sched_ext-in-linux-6-11/) https://www.phoronix.com/news/Linux-6.11-Extensible-Scheduler (https://www.phoronix.com/news/Linux-6.11-Extensible-Scheduler) Mozilla Firefox 127 Released https://www.mozilla.org/en-US/firefox/127.0/releasenotes/ (https://www.mozilla.org/en-US/firefox/127.0/releasenotes/) https://www.mozilla.org/en-US/firefox/new/ (https://www.mozilla.org/en-US/firefox/new/) https://frontpagelinux.com/news/mozilla-firefox-127-is-now-available-here-is-whats-new/ (https://frontpagelinux.com/news/mozilla-firefox-127-is-now-available-here-is-whats-new/) NetXMS 5.0.4 Released https://netxms.com/ (https://netxms.com/) https://netxms.com/release-notes (https://netxms.com/release-notes) https://frontpagelinux.com/news/netxms-5-0-4-released-for-open-source-network-monitoring... (https://frontpagelinux.com/news/netxms-5-0-4-released-for-open-source-network-monitoring-and-management/)

Shop Talk visits with Jennifer Bobbi, aka Aunt Barbara, and David Beck, who jointly wrote and directed a new film to be released this month called Regarding Us. You can view the trailer and get tickets to a screening near you on their website, https://www.regardingus.com. But first, Caught My Eye highlights a Charleston, WV bakery called the Rock City Cake Company. They're selling cookies decorated with “real life hate/homophobic” comments they received after sharing support for the LGBTQ+ community. Also, onigiri, a rice ball staple in Japan is trending as the snack is now being prepared by young women who use their sweaty armpits to shape the balls. Blake Ross, co-developer of Mozilla Firefox, is our Business Birthday.We're all business. Except when we're not.Apple Podcasts: apple.co/1WwDBrCSpotify: spoti.fi/2pC19B1iHeart Radio: bit.ly/4aza5LWTunein: bit.ly/1SE3NMbYouTube Music: bit.ly/43T8Y81Pandora: pdora.co/2pEfctjYouTube: bit.ly/1spAF5aAlso follow Tim and John on:Facebook: www.facebook.com/focusgroupradioTwitter: www.twitter.com/focusgroupradioInstagram: www.instagram.com/focusgroupradio

In this CME episode, Dr. Andrew Cutler interviews Desiree Matthews, PMHNP-BC on the importance of engaging patients across all facets of tardive dyskinesia management beginning with screening to symptoms monitoring to treatment. The role of patient experience and preferences in shared decision-making regarding treatment for tardive dyskinesia is discussed at length.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Recognize the significance of comprehensive measures that assess both healthcare practitioner-perceived severity of tardive dyskinesia symptoms and the patient-reported impact of tardive dyskinesia on daily life Engage in informed discussions with patients about the rationale behind incorporating additional medications to manage side effects arising from primary antipsychotic medication Consider all facets of patient health, including physical, mental, and social well-being, when formulating strategies for managing tardive dyskinesia symptoms Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour. Released: June 05, 2024*   Expiration: June 04, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-01-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.00 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.5 continuing education hour(s) of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour(s) (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit(s). Approval is valid until June 04, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Desiree M. Matthews, MSN, PMHNP-BC Founder and Clinical Director, Different MHP, PC, Charlotte, NC Consultant/Advisor: Alkermes, Biogen, Boehringer Ingelheim, Karuna, Indivior, Janssen Pharmaceuticals, Neurocrine Biosciences, Sage Therapeutics, Takeda, Teva Speakers Bureau: AbbVie, Axsome, Neurocrine Biosciences, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, and Andrea Zimmerman. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

This week's episode, we're going to be taking a look into the crystal ball of Linux, and we're going to be seeing into the future for the roadmaps that were given to us by various projects, like Ubuntu, GNOME, Mozilla Firefox, and others. Plus, we have some new releases like Alpine Linux and MX Linux, […]

https://youtu.be/z5afusnv-3M Forum Discussion Thread (https://forum.tuxdigital.com/t/264-ubuntu-going-wayland-for-nvidia-firefoxs-future-gnome-5-year-strat-more-linux-news/6237) This week's episode, we're going to be taking a look into the crystal ball of Linux, and we're going to be seeing into the future for the roadmaps that were given to us by various projects, like Ubuntu, GNOME, Mozilla Firefox, and others. Plus, we have some new releases like Alpine Linux and MX Linux, and a lot more to check out. So let's jump into the episode of This Week in Linux, Your Source for Linux GNews. Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/d1f28b5f-0106-46ca-8ae2-4f28362f318c.mp3) Sponsored by: Kolide - thisweekinlinux.com/kolide (https://thisweekinlinux.com/kolide) Want to Support the Show? Become a Patron = https://tuxdigital.com/membership (https://tuxdigital.com/membership) Store = https://tuxdigital.com/store (https://tuxdigital.com/store) Chapters: 00:00 Intro 00:29 Ubuntu 24.10 Wayland Default for NVidia 04:13 GNOME 5 Year Strategy 08:17 Future of Mozilla Firefox 12:10 Sponsored by LINBIT 12:57 Fedora Approves New Miracle Spin 14:50 Alpine Linux 3.20 Released 16:03 MX Linux 23.3 Released 17:07 IceWM 3.5 Released 18:46 HandBrake 1.8 Released 19:50 Atari buys Intellivision 21:40 Outro Links: Ubuntu 24.10 Wayland Default for NVidia https://discourse.ubuntu.com/t/ubuntu-desktop-s-24-10-dev-cycle-the-roadmap/45120?u=d0od (https://discourse.ubuntu.com/t/ubuntu-desktop-s-24-10-dev-cycle-the-roadmap/45120?u=d0od) https://www.omgubuntu.co.uk/2024/05/ubuntu-24-10-wayland-nvidia (https://www.omgubuntu.co.uk/2024/05/ubuntu-24-10-wayland-nvidia) https://www.omgubuntu.co.uk/2024/05/snap-store-website-new-look (https://www.omgubuntu.co.uk/2024/05/snap-store-website-new-look) https://www.omgubuntu.co.uk/2024/05/ubuntu-24-04-upgrades-officially-open (https://www.omgubuntu.co.uk/2024/05/ubuntu-24-04-upgrades-officially-open) GNOME 5 Year Strategy https://foundation.gnome.org/2024/05/23/introducing-the-gnome-foundations-five-year-strategic-plan-draft/ (https://foundation.gnome.org/2024/05/23/introducing-the-gnome-foundations-five-year-strategic-plan-draft/) https://foundation.gnome.org/strategicplan/ (https://foundation.gnome.org/strategicplan/) Future of Mozilla Firefox https://connect.mozilla.org/t5/discussions/here-s-what-we-re-working-on-in-firefox/td-p/57694 (https://connect.mozilla.org/t5/discussions/here-s-what-we-re-working-on-in-firefox/td-p/57694) https://www.omgubuntu.co.uk/2024/05/mozilla-shares-firefox-roadmap (https://www.omgubuntu.co.uk/2024/05/mozilla-shares-firefox-roadmap) Fedora Approves New Miracle Spin https://fedoraproject.org/wiki/Changes/FedoraMiracle (https://fedoraproject.org/wiki/Changes/FedoraMiracle) https://www.phoronix.com/news/Fedora-Miracle-Spin-Approved (https://www.phoronix.com/news/Fedora-Miracle-Spin-Approved) Alpine Linux 3.20 Released https://alpinelinux.org (https://alpinelinux.org) https://alpinelinux.org/posts/Alpine-3.20.0-released.html (https://alpinelinux.org/posts/Alpine-3.20.0-released.html) https://www.phoronix.com/news/Alpine-Linux-3.20 (https://www.phoronix.com/news/Alpine-Linux-3.20) MX Linux 23.3 Released https://mxlinux.org/blog/mx-23-3-libretto-released/ (https://mxlinux.org/blog/mx-23-3-libretto-released/) IceWM 3.5 Released https://github.com/ice-wm/icewm/releases/tag/3.5.0 (https://github.com/ice-wm/icewm/releases/tag/3.5.0) https://9to5linux.com/icewm-3-5-lightweight-window-manager-released-with-new-features (https://9to5linux.com/icewm-3-5-lightweight-window-manager-released-with-new-features) HandBrake 1.8 Released https://github.com/HandBrake/HandBrake/releases/tag/1.8.0 (https://github.com/HandBrake/HandBrake/releases/tag/1.8.0) https://9to5linux.com/handbrake-1-8-video-transcoder-adds-gtk4-port-on-linux-ffmpeg-7-0-support (https://9to5linux.com/handbrake-1-8-video-transcoder-adds-gtk4-port-on-linux-ffmpeg-7-0-support) Atari buys Intellivision https://atari.com/blogs/newsroom/atari-acquires-intellivision-brand (https://atari.com/blogs/newsroom/atari-acquires-intellivision-brand) https://www.gamingonlinux.com/2024/05/atari-acquires-intellivision-brand-and-over-200-games/ (https://www.gamingonlinux.com/2024/05/atari-acquires-intellivision-brand-and-over-200-games/)

https://youtu.be/DsQfPv8GqBg Forum Discussion Thread (https://forum.tuxdigital.com/t/260-lxqt-desktop-nouveau-lead-joins-nvidia-almalinux-making-waves-new-linux-tablet-more-linux-news/6210) We have some very interesting news this week, we've got a brand new major release of the LXQt desktop environment, there's a strange but potentially good twist in the ongoing saga of Nvidia and open source drivers, Red Hat drops the hardware ball and AlmaLinux catches it. Plus there's a new Linux Tablet trying to get kickstarted. All of this and more on this episode of This Week in Linux, Your Source for Linux GNews! Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/aa848458-f48e-48f5-8a66-ba5aaafce1f1.mp3) Sponsored by: Kolide - thisweekinlinux.com/kolide (https://thisweekinlinux.com/kolide) Want to Support the Show? Become a Patron = https://tuxdigital.com/membership (https://tuxdigital.com/membership) Store = https://tuxdigital.com/store (https://tuxdigital.com/store) Chapters: 00:00 Intro 00:34 LXQt 2.0 Released 02:52 Former Nouveau Lead Developer Joins NVIDIA 05:51 AlmaLinux 9.4 Beta Released 09:04 Sponsored by Kolide 10:26 Mozilla Firefox 125 Released 11:59 Volla Tablet on Kickstarter supports Ubuntu Touch 13:39 Bazzite 2.5.0 Released 15:16 XZ Backdoor Gets the All-Clear 15:44 Outro Links: LXQt 2.0 Released https://lxqt-project.org/release/2024/04/15/release-lxqt-2-0-0/ (https://lxqt-project.org/release/2024/04/15/release-lxqt-2-0-0/) https://lxqt-project.org/ (https://lxqt-project.org/) https://9to5linux.com/lxqt-2-0-desktop-environment-officially-released-this-is-whats-new (https://9to5linux.com/lxqt-2-0-desktop-environment-officially-released-this-is-whats-new) https://www.phoronix.com/news/LXQt-2.0-Released (https://www.phoronix.com/news/LXQt-2.0-Released) https://linuxiac.com/lxqt-2-0-desktop-environment/ (https://linuxiac.com/lxqt-2-0-desktop-environment/) Former Nouveau Lead Developer Joins NVIDIA https://lore.kernel.org/nouveau/20240416234002.19509-1-bskeggs@nvidia.com/ (https://lore.kernel.org/nouveau/20240416234002.19509-1-bskeggs@nvidia.com/) https://www.phoronix.com/news/Ben-Skeggs-Joins-NVIDIA (https://www.phoronix.com/news/Ben-Skeggs-Joins-NVIDIA) https://www.gamingonlinux.com/2024/04/former-nouveau-driver-lead-joins-nvidia-and-sent-a-massive-patch-set/ (https://www.gamingonlinux.com/2024/04/former-nouveau-driver-lead-joins-nvidia-and-sent-a-massive-patch-set/) https://www.phoronix.com/news/Nouveau-Maintainer-Resigns (https://www.phoronix.com/news/Nouveau-Maintainer-Resigns) AlmaLinux 9.4 Beta Released https://almalinux.org/blog/2024-04-15-announcing-94-beta/ (https://almalinux.org/blog/2024-04-15-announcing-94-beta/) https://almalinux.discourse.group/t/re-adding-support-for-older-hardware/3851 (https://almalinux.discourse.group/t/re-adding-support-for-older-hardware/3851) https://access.redhat.com/security/cve/CVE-2024-1086 (https://access.redhat.com/security/cve/CVE-2024-1086) https://jonathanspw.com/posts/2024-03-31-dealing-with-cve-2024-1086/ (https://jonathanspw.com/posts/2024-03-31-dealing-with-cve-2024-1086/) https://lwn.net/Articles/968299/ (https://lwn.net/Articles/968299/) https://www.phoronix.com/news/AlmaLinux-9.4-Beta (https://www.phoronix.com/news/AlmaLinux-9.4-Beta) Mozilla Firefox 125 Released https://www.mozilla.org/en-US/firefox/125.0.1/releasenotes/ (https://www.mozilla.org/en-US/firefox/125.0.1/releasenotes/) https://9to5linux.com/mozilla-firefox-125-is-now-available-for-download-this-is-whats-new (https://9to5linux.com/mozilla-firefox-125-is-now-available-for-download-this-is-whats-new) https://www.omgubuntu.co.uk/2024/04/mozilla-firefox-125-released (https://www.omgubuntu.co.uk/2024/04/mozilla-firefox-125-released) https://www.phoronix.com/news/Firefox-125-AV1-EME-And-More (https://www.phoronix.com/news/Firefox-125-AV1-EME-And-More) Volla Tablet on Kickstarter supports Ubuntu Touch https://9to5linux.com/volla-tablet-launches-on-kickstarter-with-support-for-ubuntu-touch (https://9to5linux.com/volla-tablet-launches-on-kickstarter-with-support-for-ubuntu-touch) https://docs.ubports.com/en/latest/userguide/dailyuse/libertine.html (https://docs.ubports.com/en/latest/userguide/dailyuse/libertine.html) https://ubports.com/en/ (https://ubports.com/en/) https://www.kickstarter.com/projects/volla/volla-tablet-simplify-your-digital-life (https://www.kickstarter.com/projects/volla/volla-tablet-simplify-your-digital-life) https://ubuntu-touch.io/ (https://ubuntu-touch.io/) Bazzite 2.5.0 Released https://bazzite.gg/ (https://bazzite.gg/) https://universal-blue.org/ (https://universal-blue.org/) https://www.gamingonlinux.com/2024/04/bazzite-v25-has-fixes-for-lenovo-legion-go-and-asus-rog-ally-plus-smoother-installs/ (https://www.gamingonlinux.com/2024/04/bazzite-v25-has-fixes-for-lenovo-legion-go-and-asus-rog-ally-plus-smoother-installs/) https://universal-blue.discourse.group/t/bazzite-2-5-0-update-released/1108 (https://universal-blue.discourse.group/t/bazzite-2-5-0-update-released/1108) https://github.com/ublue-os/bazzite/releases/tag/v2.5.0 (https://github.com/ublue-os/bazzite/releases/tag/v2.5.0) XZ Backdoor Gets the All-Clear https://fedoramagazine.org/cve-2024-3094-all-clear/ (https://fedoramagazine.org/cve-2024-3094-all-clear/) https://www.linux-magazine.com/Online/News/XZ-Gets-the-All-Clear (https://www.linux-magazine.com/Online/News/XZ-Gets-the-All-Clear)

On this spicy episode of Windows Weekly, Paul, Leo, and Richard try to pronounce "Sudo," watch an expensive Copilot ad, marvel at big Arm revenues, discuss the latest in internet browser news, and debate the FTC's motivations as they go after Microsoft once again! Windows 11 Big changes in Insider, with Canary and Dev moving to the same 24H2 builds Windows 11 is going to get its AI moment this year With the announcement of 24H2, does that mean nothing big mid-year as rumors suggested? Patch Tuesday arrives. Copilot moves to the right of the system tray after 10 seconds of testing Brave ships its browser on Arm in stable Windows will likely get an AI game upscaling feature AI/Antitrust Report: Azure is allegedly 2/3rds the size of AWS by revenue, thanks to AI Microsoft Bing and Edge avoid the EU DMA Google Gemini officially replaces Bard Grammarly lays off 230 to focus on AI Mozilla scales back dramatically, will focus on AI in Firefox Arc Sync comes to Arc on Mac only Cloud/server/dev Google One surpasses 100 million users. New AI tier is coming to take on Copilot Pro Arm revenues are in. Look at those margins! Notion acquires Skiff. Ladies and gentlemen, the Notion Office is coming .NET 9 Preview 1 arrives. Are annual updates too much? Xbox Xbox says it will come clean on its strategy The FTC claims that Xbox layoffs violate the terms of its Activision Blizzard acquisition promises Microsoft tells the court that the FTC is wrong on multiple levels There's a new Xbox system update Sony doesn't meet its quarterly PS5 sales target, will miss its annual target, and the PS5 is falling off a cliff Disney invests $1.5 billion in Epic Games. "F U, Apple!" Flight Simulator jumps the Minecraft Shark Tips and Picks Tip of the Week: Microsoft PC Manager - Avoid at all costs App Picks of the Week: DuckDuckGo browser, Apple TV+, Apple Music, Apple Devices for Windows RunAs Radio this week: Maximizing Metadata with Emily Manicini Brown liquor pick of the week: Starward Pedro Ximenez Cask Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to this show at https://twit.tv/shows/windows-weekly Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Sponsor: kolide.com/ww

On this spicy episode of Windows Weekly, Paul, Leo, and Richard try to pronounce "Sudo," watch an expensive Copilot ad, marvel at big Arm revenues, discuss the latest in internet browser news, and debate the FTC's motivations as they go after Microsoft once again! Windows 11 Big changes in Insider, with Canary and Dev moving to the same 24H2 builds Windows 11 is going to get its AI moment this year With the announcement of 24H2, does that mean nothing big mid-year as rumors suggested? Patch Tuesday arrives. Copilot moves to the right of the system tray after 10 seconds of testing Brave ships its browser on Arm in stable Windows will likely get an AI game upscaling feature AI/Antitrust Report: Azure is allegedly 2/3rds the size of AWS by revenue, thanks to AI Microsoft Bing and Edge avoid the EU DMA Google Gemini officially replaces Bard Grammarly lays off 230 to focus on AI Mozilla scales back dramatically, will focus on AI in Firefox Arc Sync comes to Arc on Mac only Cloud/server/dev Google One surpasses 100 million users. New AI tier is coming to take on Copilot Pro Arm revenues are in. Look at those margins! Notion acquires Skiff. Ladies and gentlemen, the Notion Office is coming .NET 9 Preview 1 arrives. Are annual updates too much? Xbox Xbox says it will come clean on its strategy The FTC claims that Xbox layoffs violate the terms of its Activision Blizzard acquisition promises Microsoft tells the court that the FTC is wrong on multiple levels There's a new Xbox system update Sony doesn't meet its quarterly PS5 sales target, will miss its annual target, and the PS5 is falling off a cliff Disney invests $1.5 billion in Epic Games. "F U, Apple!" Flight Simulator jumps the Minecraft Shark Tips and Picks Tip of the Week: Microsoft PC Manager - Avoid at all costs App Picks of the Week: DuckDuckGo browser, Apple TV+, Apple Music, Apple Devices for Windows RunAs Radio this week: Maximizing Metadata with Emily Manicini Brown liquor pick of the week: Starward Pedro Ximenez Cask Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to this show at https://twit.tv/shows/windows-weekly Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Sponsor: kolide.com/ww

On this spicy episode of Windows Weekly, Paul, Leo, and Richard try to pronounce "Sudo," watch an expensive Copilot ad, marvel at big Arm revenues, discuss the latest in internet browser news, and debate the FTC's motivations as they go after Microsoft once again! Windows 11 Big changes in Insider, with Canary and Dev moving to the same 24H2 builds Windows 11 is going to get its AI moment this year With the announcement of 24H2, does that mean nothing big mid-year as rumors suggested? Patch Tuesday arrives. Copilot moves to the right of the system tray after 10 seconds of testing Brave ships its browser on Arm in stable Windows will likely get an AI game upscaling feature AI/Antitrust Report: Azure is allegedly 2/3rds the size of AWS by revenue, thanks to AI Microsoft Bing and Edge avoid the EU DMA Google Gemini officially replaces Bard Grammarly lays off 230 to focus on AI Mozilla scales back dramatically, will focus on AI in Firefox Arc Sync comes to Arc on Mac only Cloud/server/dev Google One surpasses 100 million users. New AI tier is coming to take on Copilot Pro Arm revenues are in. Look at those margins! Notion acquires Skiff. Ladies and gentlemen, the Notion Office is coming .NET 9 Preview 1 arrives. Are annual updates too much? Xbox Xbox says it will come clean on its strategy The FTC claims that Xbox layoffs violate the terms of its Activision Blizzard acquisition promises Microsoft tells the court that the FTC is wrong on multiple levels There's a new Xbox system update Sony doesn't meet its quarterly PS5 sales target, will miss its annual target, and the PS5 is falling off a cliff Disney invests $1.5 billion in Epic Games. "F U, Apple!" Flight Simulator jumps the Minecraft Shark Tips and Picks Tip of the Week: Microsoft PC Manager - Avoid at all costs App Picks of the Week: DuckDuckGo browser, Apple TV+, Apple Music, Apple Devices for Windows RunAs Radio this week: Maximizing Metadata with Emily Manicini Brown liquor pick of the week: Starward Pedro Ximenez Cask Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to this show at https://twit.tv/shows/windows-weekly Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Sponsor: kolide.com/ww

On this spicy episode of Windows Weekly, Paul, Leo, and Richard try to pronounce "Sudo," watch an expensive Copilot ad, marvel at big Arm revenues, discuss the latest in internet browser news, and debate the FTC's motivations as they go after Microsoft once again! Windows 11 Big changes in Insider, with Canary and Dev moving to the same 24H2 builds Windows 11 is going to get its AI moment this year With the announcement of 24H2, does that mean nothing big mid-year as rumors suggested? Patch Tuesday arrives. Copilot moves to the right of the system tray after 10 seconds of testing Brave ships its browser on Arm in stable Windows will likely get an AI game upscaling feature AI/Antitrust Report: Azure is allegedly 2/3rds the size of AWS by revenue, thanks to AI Microsoft Bing and Edge avoid the EU DMA Google Gemini officially replaces Bard Grammarly lays off 230 to focus on AI Mozilla scales back dramatically, will focus on AI in Firefox Arc Sync comes to Arc on Mac only Cloud/server/dev Google One surpasses 100 million users. New AI tier is coming to take on Copilot Pro Arm revenues are in. Look at those margins! Notion acquires Skiff. Ladies and gentlemen, the Notion Office is coming .NET 9 Preview 1 arrives. Are annual updates too much? Xbox Xbox says it will come clean on its strategy The FTC claims that Xbox layoffs violate the terms of its Activision Blizzard acquisition promises Microsoft tells the court that the FTC is wrong on multiple levels There's a new Xbox system update Sony doesn't meet its quarterly PS5 sales target, will miss its annual target, and the PS5 is falling off a cliff Disney invests $1.5 billion in Epic Games. "F U, Apple!" Flight Simulator jumps the Minecraft Shark Tips and Picks Tip of the Week: Microsoft PC Manager - Avoid at all costs App Picks of the Week: DuckDuckGo browser, Apple TV+, Apple Music, Apple Devices for Windows RunAs Radio this week: Maximizing Metadata with Emily Manicini Brown liquor pick of the week: Starward Pedro Ximenez Cask Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to this show at https://twit.tv/shows/windows-weekly Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Sponsor: kolide.com/ww

On this spicy episode of Windows Weekly, Paul, Leo, and Richard try to pronounce "Sudo," watch an expensive Copilot ad, marvel at big Arm revenues, discuss the latest in internet browser news, and debate the FTC's motivations as they go after Microsoft once again! Windows 11 Big changes in Insider, with Canary and Dev moving to the same 24H2 builds Windows 11 is going to get its AI moment this year With the announcement of 24H2, does that mean nothing big mid-year as rumors suggested? Patch Tuesday arrives. Copilot moves to the right of the system tray after 10 seconds of testing Brave ships its browser on Arm in stable Windows will likely get an AI game upscaling feature AI/Antitrust Report: Azure is allegedly 2/3rds the size of AWS by revenue, thanks to AI Microsoft Bing and Edge avoid the EU DMA Google Gemini officially replaces Bard Grammarly lays off 230 to focus on AI Mozilla scales back dramatically, will focus on AI in Firefox Arc Sync comes to Arc on Mac only Cloud/server/dev Google One surpasses 100 million users. New AI tier is coming to take on Copilot Pro Arm revenues are in. Look at those margins! Notion acquires Skiff. Ladies and gentlemen, the Notion Office is coming .NET 9 Preview 1 arrives. Are annual updates too much? Xbox Xbox says it will come clean on its strategy The FTC claims that Xbox layoffs violate the terms of its Activision Blizzard acquisition promises Microsoft tells the court that the FTC is wrong on multiple levels There's a new Xbox system update Sony doesn't meet its quarterly PS5 sales target, will miss its annual target, and the PS5 is falling off a cliff Disney invests $1.5 billion in Epic Games. "F U, Apple!" Flight Simulator jumps the Minecraft Shark Tips and Picks Tip of the Week: Microsoft PC Manager - Avoid at all costs App Picks of the Week: DuckDuckGo browser, Apple TV+, Apple Music, Apple Devices for Windows RunAs Radio this week: Maximizing Metadata with Emily Manicini Brown liquor pick of the week: Starward Pedro Ximenez Cask Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to this show at https://twit.tv/shows/windows-weekly Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Sponsor: kolide.com/ww

On this spicy episode of Windows Weekly, Paul, Leo, and Richard try to pronounce "Sudo," watch an expensive Copilot ad, marvel at big Arm revenues, discuss the latest in internet browser news, and debate the FTC's motivations as they go after Microsoft once again! Windows 11 Big changes in Insider, with Canary and Dev moving to the same 24H2 builds Windows 11 is going to get its AI moment this year With the announcement of 24H2, does that mean nothing big mid-year as rumors suggested? Patch Tuesday arrives. Copilot moves to the right of the system tray after 10 seconds of testing Brave ships its browser on Arm in stable Windows will likely get an AI game upscaling feature AI/Antitrust Report: Azure is allegedly 2/3rds the size of AWS by revenue, thanks to AI Microsoft Bing and Edge avoid the EU DMA Google Gemini officially replaces Bard Grammarly lays off 230 to focus on AI Mozilla scales back dramatically, will focus on AI in Firefox Arc Sync comes to Arc on Mac only Cloud/server/dev Google One surpasses 100 million users. New AI tier is coming to take on Copilot Pro Arm revenues are in. Look at those margins! Notion acquires Skiff. Ladies and gentlemen, the Notion Office is coming .NET 9 Preview 1 arrives. Are annual updates too much? Xbox Xbox says it will come clean on its strategy The FTC claims that Xbox layoffs violate the terms of its Activision Blizzard acquisition promises Microsoft tells the court that the FTC is wrong on multiple levels There's a new Xbox system update Sony doesn't meet its quarterly PS5 sales target, will miss its annual target, and the PS5 is falling off a cliff Disney invests $1.5 billion in Epic Games. "F U, Apple!" Flight Simulator jumps the Minecraft Shark Tips and Picks Tip of the Week: Microsoft PC Manager - Avoid at all costs App Picks of the Week: DuckDuckGo browser, Apple TV+, Apple Music, Apple Devices for Windows RunAs Radio this week: Maximizing Metadata with Emily Manicini Brown liquor pick of the week: Starward Pedro Ximenez Cask Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Download or subscribe to this show at https://twit.tv/shows/windows-weekly Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Check out Paul's blog at thurrott.com The Windows Weekly theme music is courtesy of Carl Franklin. Sponsor: kolide.com/ww

Neuralink, één van Elon Musks bedrijven, heeft voor het eerst bij een mens een hersenimplantaat ingebracht. Musk meldde de mijlpaal zelf op X. Het implantaat is op zondag geplaatst en de eerste tekenen zijn volgens Musk "veelbelovend". Met Neuralink wil Musk het brein rechtstreeks laten communiceren met een computer. Het bedrijf probeert volgens de miljardair met die technologie verlamde mensen in staat te stellen hun spieren weer te bewegen en mensen die blind zijn geworden hun zicht terug te geven. Details over de persoon die het implantaat ontving, gaf Musk niet prijs. Neuralink wil vooralsnog ook niet reageren op vragen van Amerikaanse media. Neuralink bestaat sinds 2016. De medische toezichthouder FDA gaf het bedrijf vorig jaar toestemming om de technologie te testen op mensen. Neuralink wil de implantaten uiteindelijk ook gebruiken om mensen met ziektes als ALS en Parkinson of slachtoffers van een beroerte te helpen met communicatie. Verder in deze Tech Update: In de EU kun je écht andere internetbrowsers zoals Google Chome en Mozilla Firefox gaan gebruiken op je iPhone, afgedwongen door de Digital Markets Act - eerder draaiden die nog steeds op Apple's WebKit-engine, vanaf heden moet via een toelatingsproces ook een eigen eigen kunnen worden gebruikt TikTok gaat YouTube achterna en promoot nu langere en zelfs horizontale video's See omnystudio.com/listener for privacy information.

https://youtu.be/5KqAHwlxDpE Forum Discussion Thread (https://forum.tuxdigital.com/t/250-gentoo-linux-firefox-122-parrot-os-valve-proton-more-linux-news/6135) On this episode of TWIL (250), Gentoo Linux has some made some major changes to their distro. Mozilla has released a new version of Firefox including DEB packages for those non-snap users out there. Ethical hacking distro Parrot OS has a new version out. Plus we've got news from Valve, Lutris and many more for some gaming news. All of this and more on this episode of This Week in Linux, Your Source for Linux GNews! Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/e9845689-3446-4ca9-9609-743aa67453f6.mp3) Supported by: Kolide = https://thisweekinlinux.com/kolide (https://thisweekinlinux.com/kolide) Want to Support the Show? Become a Patron = https://tuxdigital.com/membership (https://tuxdigital.com/membership) Store = https://tuxdigital.com/store (https://tuxdigital.com/store) Chapters: 00:00 Introduction 00:36 Mozilla Firefox 122.0 Released - [release notes (https://www.mozilla.org/en-US/firefox/122.0/releasenotes/), 4 reasons (https://blog.mozilla.org/en/products/4-reasons-to-try-mozillas-new-firefox-linux-package-for-ubuntu-and-debian-derivatives/)] 05:34 Gentoo Linux Progress from 2023 - [link (https://www.gentoo.org/news/2024/01/22/new-year.html)] 08:28 Parrot 6.0 Released - [link (https://parrotsec.org/blog/2024-01-24-parrot-6.0-release-notes)] 10:20 MX Linux 23.2 “Libretto” Released - [link (https://mxlinux.org/blog/mx-23-2-libretto-released/)] 12:37 Linux Mint 21.3 “EDGE” ISO Released - [link (https://blog.linuxmint.com/?p=4635)] 13:45 KOLIDE - [link ()] 15:07 openSUSE Slowroll Misunderstandings Clarified - [link (https://news.opensuse.org/2024/01/19/clarifying-misunderstandings-of-slowroll/)] 16:30 BunsenLabs Linux Boron Released - [link (https://forums.bunsenlabs.org/viewtopic.php?id=8825)] 18:10 Valve Releases Proton 8.0-5 - [link (https://github.com/ValveSoftware/Proton/releases/tag/proton-8.0-5c)] 19:27 Lutris 0.5.15 Released - [link (https://github.com/lutris/lutris/releases/tag/v0.5.15)] 20:58 Godot Engine offers free Nintendo Switch port - [link (https://www.rawrlab.com/godot_nintendo_switch_free_port.html), gamingonlinux (https://www.gamingonlinux.com/2024/01/godot-engine-gets-a-free-nintendo-switch-port-for-game-devs/)] 22:50 AYANEO's New NES-Style Mini PC - [link (https://www.ayaneo.com/product/AYANEO-Retro-Mini-PC-AM02.html), omgubuntu (https://www.omgubuntu.co.uk/2024/01/ayaneo-am02-mini-pc-nes)] 25:59 libvirt 10.0 Released - [link (https://libvirt.org/news.html)] 26:55 Huawei claims about HarmonyOS NEXT kernel - [link (https://www.huaweicentral.com/huaweis-self-developed-harmony-kernel-is-3-times-more-efficient-than-linux/)] 29:01 Outro

This 45-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 15-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-pathophysiology/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 30-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-treatment-options/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.org Copyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Free, ungated access to all 290+ episodes of “It's 5:05!” on your favorite podcast platforms: https://bit.ly/505-updates. You're welcome to

https://youtu.be/EzJpm9YCL4c Forum Discussion Thread (https://forum.tuxdigital.com/t/243-inkscape-lts-kernels-endeavouros-firefox-120-steam-sale-amp-more-linux-news/6074) On this episode of TWIL (243), Inkscape is celebrating 20 years of the project. The Linux Kernel has confirmed which version will be the next LTS. EndeavourOS just release a brand new version. Lock up your wallets because the 2023 Steam Autumn Sale just launched. All of this and more on this episode of This Week in Linux, Your Source for Linux GNews! Download as MP3 (https://aphid.fireside.fm/d/1437767933/2389be04-5c79-485e-b1ca-3a5b2cebb006/c5abf30c-3258-4c41-a5cc-81b85e46968b.mp3) Supported by: LINBIT = https://thisweekinlinux.com/linbit Want to Support the Show? Become a Patron = https://tuxdigital.com/membership Store = https://tuxdigital.com/store Chapters: 00:00 TWIL 243 Intro 00:35 Inkscape Celebrates 20 Years - [ link (https://inkscape.org/news/2023/11/18/big-small-release-inkscape-131-is-out/) ] 02:04 Linux Kernel 6.6 Confirmed as an LTS - [ link (https://www.kernel.org/category/releases.html) ] 03:54 EndeavourOS ‘Galileo' Released - [ link (https://endeavouros.com/news/slimmer-options-but-lean-and-in-a-new-live-environment-galileo-has-arrived/) ] 06:34 Mozilla Firefox 120 Released - [ 120 (https://www.mozilla.org/en-US/firefox/120.0/releasenotes/), git (https://www.phoronix.com/news/Firefox-Going-Git), wayland (https://www.phoronix.com/news/Firefox-Change-Wayland-Release), accounts (https://blog.mozilla.org/en/mozilla/firefox-accounts-transition-mozilla-accounts/), ff on android (https://blog.mozilla.org/addons/2023/08/10/prepare-your-firefox-desktop-extension-for-the-upcoming-android-release/) ] 08:45 Steam Autumn Sale 2023 - [ link (https://store.steampowered.com/) ] 10:38 LINBIT 12:03 Calibre 7.0 E-Book Manager Released - [ link (https://calibre-ebook.com/whats-new) ] 13:22 Distrobox 1.6 Released - [ link (https://github.com/89luca89/distrobox/releases/tag/1.6.0) ] 14:50 HandBrake 1.7 Released - [ link (https://handbrake.fr/) ] 16:07 Open-Source NVIDIA “NVK” Driver Is Now Conformant For Vulkan 1.0 - [ link (https://www.gamingonlinux.com/2023/11/open-source-nvidia-vulkan-driver-nvk-hits-vulkan-10-conformance/) ] 17:21 Outro

In this episode of This Week in Linux (235), we cover exciting news: Raspberry Pi 5 Announced, Shorter LTS Kernel Maintenance, GNU's 40th Anniversary, LINBIT, openSUSE's Slowroll Distro & Survey, Mozilla Firefox 118 Released. All of this and more on this episode of This Week in Linux, Your Source for Linux GNews! Download as MP3 […]

"I have been at the inception points of three companies-Intuit, Netflix and Mozilla Firefox. And now I'm just trying to give back as many lessons as possible” Jim Cook  Jim Cook shares his front row experience as first finance hire at streaming giant Netflix. He reveals the finance business partnering lessons learned from supporting fellow co-founders Marc Randolph and Reed Hastings building the company from obscurity to one of the biggest brands in the world. How did finance at Netflix contribute to the  design of  the first red envelopes? What are his lessons that can transform your FP&A? In this episode: Coping with unrealistic budgets experience at fast-growing startups What it's like as Finance Hire #1 at Netflix Rebirthing the browser market at Mozilla Firefox Lessons from M&A and IPO at Intuit   Lessons to deliver blockbuster FP&A  The FP&A as CEO  The power of a “listening tour and finance partnership” Using your voice in FP&A  What storytelling really means for a finance professional Two strategic finance moments that changed the game for Intuit and Mozilla Links from the Show Netflixed by Gina Keating (Amazon) That Will Never Work, Mark Randolph (Amazon) Netflix versus the World. (Full Documentary, YouTube) Five lessons I learned from Netflix – Jim Cook Contact Jim Cook on LinkedIn Email jimCook@benchboard.com

In this video, we compare Arc Browser, a unique browser by the Browser Company of New York, with the popular Google Chrome. Join me as I explore what makes Arc different from the usual suspects like Google Chrome, Microsoft Edge, Mozilla Firefox, and Safari. What Makes The Arc Browser Unique When Compared To Google Chrome: 1. The team behind ARC: Discover what makes the team behind ARC so unique, and how their backgrounds contribute to the browser's innovation and design. 2. ARC vs. Google Chrome: Take a deep dive into ARC's user interface (UI) and user experience (UX) and find out why it's considered one of the most beautiful browsing experiences out there. Learn how ARC, built upon the Chromium base, competes and differentiates itself from the popular Google Chrome. 3. Unique Features: Explore the various features that set Arc Browser apart, such as the sidebar, pin tabs, see upcoming events preview, Gmail previews, and organize your tabs with profiles and spaces for a cleaner and more organized browsing experience. 4. Initial Impressions: I'll share my first encounter with Arc Browser, why it didn't initially stick with him, and how I gave it a second chance to see if it could replace his go-to browser, Google Chrome. 5. Pros and Cons: Get an honest rundown of my frustrations and what I love about using Arc Browser, allowing you to make an informed decision about whether Arc is the right browser for you. Learn more about the Arc Browser and experience its unique browsing features by visiting (my invite link): https://arc.net/gift/a43a843a Have you tried the Arc Browser? Did it win you over or are you sticking with your current browser? Let us know by leaving a comment on our website or reaching out on social media.

In this milestone 100th episode, Chuck and Robbie are joined by a round table of industry experts and web developers with different philosophies, preferences, and experiences in the tech space to share their opinions on the state of web development. The round table includes Chris Coyier, Co-Founder of CodePen; Scott Tolinski, former Owner of Level Up Tutorials; Tracy Lee, CEO and Co-Founder of This Dot Labs; and Wes Bos, Founder of BosType Inc. The panel shares their opinions on the state of web development, reflecting on the journey from vanilla JavaScript to the rise of Tailwind CSS. They delve into the impact of Tailwind CSS on modern web development, discuss exciting new front-end APIs like the View Transitions API and Anchor Positioning API, and emphasize the importance of mastering JavaScript fundamentals. In this episode, Robbie and Chuck bring industry experts together for a captivating discussion filled with valuable insights on the evolution of front-end development, new web technologies, and their interests outside of web development. Key Takeaways [01:43] - An introduction to the round table of industry experts. [03:47] - A whiskey review: Sagamore and Benchmark. [07:00] - Tech hot takes. [21:14] - Scott's experience using popover API. [23:18] - Chuck discusses Chris' talk at RenderATL. [24:38] - How ChatGPT is negatively affecting Mozilla Firefox. [28:21] - What each guest would do if they weren't in web development? [32:46] - Interesting topics on Chuck's Twitter feed. [40:46] - What makes a milk? Quotes [09:11] - “CSS is getting so complex now that it has to be compiled.” ~ Wes Bos [23:15] - “Yeah, man, HTML rules.” ~ Scott Tolinski [25:33] - “People stopped using Google as much, they're going to AI.” ~ Wes Bos Links Chris Coyier Chris Coyier Twitter Chris Coyier LinkedIn Wes Bos Wes Bos Twitter Wes Bos LinkedIn Scott Tolinski Scott Tolinski Twitter Scott Tolinski LinkedIn Tracy Lee Twitter Tracy Lee LinkedIn Kelly Vaughn Twitter Kelly Vaughn LinkedIn RenderATL CodePen Syntax Podcast Level Up Tutorials This Dot Labs Modern Web Sentry Sagamore Spirit Benchmark Kentucky Straight Bourbon Tailwind CSS Twitter Nuxt Angular React JS jQuery Ember Netflix Rust Microsoft Safari Mozilla Firefox WWCD23 Google Apple ChatGPT IMBD Adobe After Effects The Dalmore 12 Ken Wheeler Nike Trader Joe's Smartless Podcast BlackRock Ferrari Make-A-Wish Foundation Apple News Connect with our hosts Robbie Wagner Chuck Carpenter Ship Shape Subscribe and stay in touch Apple Podcasts Spotify Google Podcasts Whiskey Web and Whatnot Top-Tier, Full-Stack Software Consultants This show is brought to you by Ship Shape. Ship Shape's software consultants solve complex software and app development problems with top-tier coding expertise, superior service, and speed. In a sea of choices, our senior-level development crew rises above the rest by delivering the best solutions for fintech, cybersecurity, and other fast-growing industries. Check us out at shipshape.io.

Victor Storchan est le lead d'intelligence Artificielle chez Mozilla (Firefox), expert en Machine Learning, CEO d'une structure qu'il a créé et dédiée à l'IA (Althiqa). Bref, il fait parti de ces excellents professionnels français spécialistes de l'intelligence artificielle. Depuis que Chat GPT a sorti sa première beta, j'ai l'impression que le grand public a enfin appris que l'intelligence artificielle était une réalité. Ou peut-être que c'est que dans ma bulle, c'est aussi possible. Pourtant, cette vidéo qui date de 2014 (9 ans donc) expliquait déjà tout cela très bien. D'ailleurs, elle avait un nom très clair : human need not apply. Pourtant si tout le monde a déjà un avis très tranché (est-ce qu'il est possible de dire qu'on ne sait pas trop encore aujourd'hui ou qu'on a un avis nuancé?) sur le sujet, je crois que beaucoup de personnes ne savent pas précisément de quoi il en retourne. J'ai déjà fait plusieurs épisodes sur l'IA que je vais mettre en lien avec cet épisode mais je voulais revenir aux bases et explorer aussi de quoi l'on parle, où est ce que l'on va, les conséquences que cela va avoir sur l'école et l'apprentissage de manière générale, sur le travail, sur la médecine et surtout de nombreuses industries. Avec Victor nous traitons de beaucoup de sujets et j'ai essayé de poser les questions que vous devriez vraiment vous poser: Pourquoi parle-t-on autant de Chat GPT ? Est-ce que l'on peut parler "d'intelligence" quand on fait référence à Chat GPT ? Comment fonctionne le machine learning ? Qui nourrit les bases de données ? Qui sont les humains qui apprennent aux machines ? On utilise des personnes précaires pour nourrir des machines afin de les rendre encore plus précaires ? Quels sont les usages d'un IA de langage comme Chat GPT ? Est-ce que c'est vraiment proche de ce qu'un humain pourrait faire ? L'IA va-t-elle remplacer les humains ? Faut-il se méfier des réponses de chat GPT ? Pourquoi et comment une IA peut déraper ? Comment ne pas intégrer de biais cognitifs dans l'IA et dans chat GPT ? Quelles sont les bonnes valeurs pour avoir une IA éthique ? Pourquoi la problématique de l'IA amène généralement des problématiques de géopolitiques? Que peut faire chat GPT ? Qu'est ce qui c'est passé en 2012 dans le monde de l'IA ? Vers quel genre de job un adolescent doit se diriger dans un monde ou l'IA prend de la place? l'IA nous oblige-t-elle a devenir plus humain? Peut-on envisager d'avoir une relation amoureuse avec une IA comme dans le film Her? Pourquoi est-ce un problème qui l'IA apprenne via les médias sociaux? Quelles sont toutes les choses que le grand public ne voit dans l'évolution de l'IA? Peux-tu expliquer Dall-E? Peux-tu expliquer Github copilot? Suggestion d'autres épisodes à écouter : Vlan #56 Ethique et intelligence artificielle sont elles compatibles?  avec Aurélie Jean (https://audmns.com/mYmYlUh) #146 Comment l'intelligence artificielle peut réellement vous rendre plus humain.e avec Alexandre Pachulski (https://audmns.com/KdwwONa) #141 Les technologies et l'intelligence artificielle face à la crise climatique avec Luc Julia (https://audmns.com/WJCdimQ)

In this episode of the Market Dominance Guys podcast, Chris, Corey and Helen Fanucci discuss the evolution of the internet, from its early days as a way for messages to move across networks to the democratization of global information through the browser and search engines. They also explore the capabilities of ChatGPT, including its ability to generate email responses and interact with customers using personalized prompts. They highlight the potential of ChatGPT to save time and improve the quality of communication for sales professionals. Join us for this idea-filled episode, "How ChatGPT Can Improve Sales Enablement."   Four ideas on how sales professionals can benefit from using ChatGPT for follow-up: Personalized Follow-Up: ChatGPT can help sales professionals create personalized follow-up messages for each customer based on their preferences, interests, and past interactions with the sales team. ChatGPT can analyze the customer's conversation history and provide personalized responses that feel like a human wrote them. Lead Nurturing: ChatGPT can help sales professionals nurture leads by sending automated follow-up messages to potential customers at regular intervals. These messages can be customized to meet the specific needs of each customer, making it easier to keep them engaged with the sales process. Schedule Meetings: ChatGPT can help sales professionals schedule meetings with potential customers by automating the process of finding a mutually convenient time to meet. This can save the sales team a lot of time and effort by eliminating the need to go back and forth with customers trying to find a suitable time. Provide Instant Customer Support: ChatGPT can be used to provide instant customer support to customers who have questions or concerns about a product or service. Sales professionals can use ChatGPT to respond to these inquiries in real-time, providing customers with the information they need to make a purchasing decision. This can help increase customer satisfaction and improve the chances of closing a sale. The Evolution of the Internet and Digital Communications 1960s: The concept of hypertext is introduced by Ted Nelson. 1980: Tim Berners-Lee develops the idea of a "mesh" network of hyperlinked documents and begins working on the WorldWideWeb (WWW) project. 1990: The first web page is created by Tim Berners-Lee. It contains information about the WWW project and how to use a web browser. 1991: The first web browser, called WorldWideWeb, is developed by Tim Berners-Lee. It was a text-only browser and was only available on the NeXTSTEP operating system. 1993: The first graphical web browser, called Mosaic, is released by Marc Andreessen and Eric Bina. It was a huge success and helped to popularize the web. 1994: The first search engine, called WebCrawler, is launched by Brian Pinkerton. It was the first search engine to index entire web pages rather than just titles and headings. 1995: Netscape Navigator is released by Netscape Communications Corporation. It becomes the most popular web browser and sets the standard for web browsing features. 1996: The first version of Internet Explorer is released by Microsoft, marking the beginning of the "browser wars" between Microsoft and Netscape. 1998: Google is founded by Larry Page and Sergey Brin. Their search engine quickly becomes the most popular and sets a new standard for search technology. 2003: Skype is launched, becoming one of the first and most popular VoIP (Voice over Internet Protocol) services. 2004: Mozilla Firefox is released by the Mozilla Foundation as an open-source alternative to Internet Explorer. 2008: Google releases the first version of the Chrome browser, which quickly becomes popular due to its speed and simplicity. 2009: WhatsApp is launched, providing a new way for people to communicate via instant messaging and voice calls over the internet. 2010: Microsoft releases Internet Explorer 9, which is considered a major improvement over previous versions. 2013: Google's Chrome becomes the most popular web browser, surpassing Internet Explorer for the first time. 2021: The current versions of popular web browsers include Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge, and Opera. Popular search engines include Google, Bing, Yahoo, and DuckDuckGo. VOIP services like Skype, Zoom, and Teams have become critical tools for remote communication in response to the COVID-19 pandemic. The Worldwide Web continues to evolve and expand, with new technologies and innovations being introduced regularly. 2022: ChatGPT from OpenAI.com takes the world by storm and changes how we write and communicate forever.